In clinical trials, there is a critical advancement in the usage of targeted NIR imaging agents that bind specifically to the EGFRs for head and neck tumor (NCT01987375), folate receptor for ovarian (NCT02317705), and PSMA for prostate cancer (NCT02048150) respectively. This evidence concerns the gene FOLH1 and prostate cancer.